A thiosemicarbazone derivative induces triple negative breast cancer cell apoptosis: possible role of miRNA‑125a‑5p and miRNA‑181a‑5p

다국어 초록 (Multilingual Abstract)

Background Breast cancer, the most commonly diagnosed malignancy in women, accounts for the highest cancer-related deaths worldwide. Triple negative breast cancer (TNBC), lacking the expression of estrogen, progesterone and HER2 receptors, has an aggressive clinical phenotype and is susceptible to chemotherapy but not to hormonal or targeted immunotherapy.
In an attempt to identify potent and selective anti-TNBC agents, a set of thiosemicarbazone derivatives were screened for their cytotoxic activity against MDA-MB 231 breast cancer cell line.
Methods MTT assay was used to examine cell viability. P53 phosphorylation status, poly (ADP-ribose) polymerase (PARP) cleavage as well as Bcl2 and Bax protein levels were assessed by Western blot. Quantitative Real Time-PCR was carried out to characterize miRNAs expression levels.
Results Combining Cisplatin + thiosemicarbazone compound 4 showed potent anti-TNBC potential. Cisplatin + compound 4 significantly enhanced p53 phosphorylation, induced Bax amount, reduced Bcl2 protein levels, enhanced PARP cleavage and modulated miRNAs expression profile in TNBCs, with a particular overexpression of miR-125a-5p and miR-181a-5p.
Intriguingly, miR-125a-5p and miR-181a-5p could significantly downregulate BCL2 expression by binding to their target sites in the 3′UTR.
Conclusions Collectively, our results demonstrate an anti-TNBC activity of Cisplatin + thiosemicarbazone compound 4 combination mediated via induction of apoptosis.

참고문헌 (Reference)

1 Zhang B, "microRNAs as oncogenes and tumor suppressors" 302 : 1-12, 2007

2 Iorio MV, "microRNA-205 regulates HER3 in human breast cancer" 69 : 2195-2200, 2009

3 Yang D, "miR-125b-5p enhances chemotherapy sensitivity to cisplatin by down-regulating Bcl2 in gallbladder cancer" 7 : 43109-, 2017

4 Willimott S, "miR-125b and miR-155 contribute to BCL2 repression and proliferation in response to CD40 ligand(CD154)in human leukemic B-cells" 287 : 2608-2617, 2012

5 Tong Z, "miR-125a-5p inhibits cell proliferation and induces apoptosis in colon cancer via targeting BCL2, BCL2L12 and MCL1" 75 : 129-136, 2015

6 Carey L, "Triple-negative breast cancer: disease entity or title of convenience?" 7 : 683-692, 2010

7 Hudis CA, "Triple-negative breast cancer: an unmet medical need" 16 (16): 1-11, 2011

8 Podo F, "Triple-negative breast cancer : present challenges and new perspectives" 4 : 209-229, 2010

9 Boyle P, "Triple-negative breast cancer : epidemiological considerations and recommendations" 23 (23): iv7-iv12, 2012

10 Chacón RD, "Triple-negative breast cancer" 12 : S3-, 2010

11 Hudis CA, "Trastuzumab—mechanism of action and use in clinical practice" 357 : 39-51, 2007

12 Pelosi G, "Thiosemicarbazone metal complexes : from structure to activity" 3 : 16-28, 2010

13 Hu W, "The regulation of multiple p53 stress responses is mediated through MDM2" 3 : 199-208, 2012

14 Eliaš J, "The p53 protein and its molecular network: modelling a missing link between DNA damage and cell fate" 1844 : 232-247, 2014

15 Mollereau B, "The p53 control of apoptosis and proliferation : lessons from Drosophila" 19 : 1421-1429, 2014

16 Kalinowski DS, "The evolution of iron chelators for the treatment of iron overload disease and cancer" 57 : 547-583, 2005

17 Chen G-Q, "Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin" 27 : 406-415, 2010

18 Hu W, "Synthesis and anticancer activity of thiosemicarbazones" 16 : 2213-2218, 2006

19 Parker JS, "Supervised risk predictor of breast cancer based on intrinsic subtypes" 27 : 1160-1167, 2009

20 Kaufmann SH, "Specific proteolytic cleavage of poly(ADP-ribose)polymerase : an early marker of chemotherapy-induced apoptosis" 53 : 3976-3985, 1993

21 Raisch J, "Role of micro-RNAs in the immune system, inflammation and cancer" 19 : 2985-2996, 2013

22 Liedtke C, "Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer" 26 : 1275-1281, 2008

23 Carey LA, "Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study" 295 : 2492-2502, 2006

24 Purdie CA, "Progesterone receptor expression is an independent prognostic variable in early breast cancer : a populationbased study" 110 : 565-572, 2014

25 Baselga J, "Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neuoverexpressing metastatic breast cancer" 14 : 737-744, 1996

26 Murren J, "Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors" 9 : 4092-4100, 2003

27 Kamangar F, "Patterns of cancer incidence, mortality, and prevalence across five continents : defining priorities to reduce cancer disparities in different geographic regions of the world" 24 : 2137-2150, 2006

28 Cho WCS, "OncomiRs : the discovery and progress of microRNAs in cancers" 6 : 60-, 2007

29 Buolamwini JK, "Novel anticancer drug discovery" 3 : 500-509, 1999

30 Vandresen F, "Novel R-(+)-limonene-based thiosemicarbazones and their antitumor activity against human tumor cell lines" 79 : 110-116, 2014

31 Rimawi MF, "Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006" 31 : 1726-1731, 2013

32 Westphal D, "Molecular biology of Bax and Bak activation and action" 1813 : 521-531, 2011

33 Hummel R, "MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types" 46 : 298-311, 2010

34 Zhou M, "MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of proapoptotic Bcl-2 antagonist killer 1(Bak1)expression" 285 : 21496-21507, 2010

35 Peña-Chilet M, "MicroRNA profile in very young women with breast cancer" 14 : 529-, 2014

36 Iorio MV, "Micro-RNA gene expression deregulation in human breast cancer" 65 : 7065-7070, 2005

37 Zhu DX, "MiR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes" 33 : 1294-1301, 2012

38 Wong R, "Isothiocyanates from tosyl chloride mediated decomposition of in situ generated dithiocarbamic acid salts" 72 (72): 3969-3971, 2007

39 Kumar MS, "Impaired micro-RNA processing enhances cellular transformation and tumorigenesis" 39 : 673-677, 2007

40 Leivonen S-K, "High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth" 8 : 93-104, 2014

41 Yogesh Bendale, "Evaluation of cytotoxic activity of platinum nanoparticles against normal and cancer cells and its anticancer potential through induction of apoptosis" 한국한의학연구원 6 (6): 141-148, 2017

42 Bartlett JMS, "Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy : a prospectively powered pathology study in the tamoxifen and exemestane adjuvant multinational trial" 29 : 1531-1538, 2011

43 Bisceglie F, "Effects of polar substituents on the biological activity of thiosemicarbazone metal complexes" 179 : 60-70, 2018

44 Pinto MCX, "Discovery of cytotoxic and pro-apoptotic compounds against leukemia cells : tert-butyl-4-[(3-nitrophenoxy)methyl]-2, 2-dimethyloxazolidine-3-carboxylate" 89 : 786-794, 2011

45 Varamini P, "Cytotoxic evaluation of four haplophyllum. species with various tumor cell lines" 45 : 299-302, 2007

46 Yu Y, "Chelators at the cancer coalface : desferrioxamine to Triapine and beyond" 12 : 6876-6883, 2006

47 Schmittgen TD, "Analyzing real-time PCR data by the comparative C(T)method" 3 : 1101-1108, 2008

48 Livak KJ, "Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T))Method" 25 : 402-408, 2001

49 Pogribny IP, "Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin" 127 : 1785-1794, 2010

50 Joensuu H, "Adjuvant treatments for triple-negative breast cancers" 23 (23): vi40-vi45, 2012

51 Oakman C, "Adjuvant systemic treatment for individual patients with triple negative breast cancer" 20 (20): S135-S141, 2011

52 Yao G, "ATM–p53 pathway causes G2/M arrest, but represses apoptosis in pseudolaric acid B-treated HeLa cells" 558 : 51-60, 2014